Is CT-388 available for purchase?

No. CT-388 is an early-stage investigational compound with a proprietary sequence owned by Roche/Genentech. It is not available from any research chemical vendor and can only be accessed through clinical trials. Phase 3 trials are planned for 2026.

How does CT-388 compare to tirzepatide?

Both are dual GLP-1/GIP agonists, but CT-388 uses a signal-biased approach that minimizes beta-arrestin recruitment. Phase 2 CT-388 data showed 22.5% weight loss at 48 weeks (comparable to tirzepatide's 20.9% at 72 weeks in SURMOUNT-1), with no weight loss plateau observed. However, CT-388 data is from Phase 2 only, and direct comparison requires Phase 3 confirmation.

What does signal-biased agonism mean for CT-388?

Signal-biased agonism means CT-388 preferentially activates G-protein signaling pathways while minimizing beta-arrestin recruitment. This may result in sustained receptor sensitivity (less tolerance development), potentially explaining the no-plateau observation in Phase 2. Whether this translates to clinically meaningful advantages over conventional agonists requires Phase 3 data.

CT-388: Community Protocols & Reports

Aggregated community experiences, protocols, and stacking patterns

Anecdotal Reports0

Community-Sourced Information

The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.

For peer-reviewed dosing protocols, see the clinical dosing guide.

Browse community protocols for all 130 peptides →

✓Reviewed byEditorial Team

📅Updated February 16, 2026

Unverified

📌TL;DR

•Community protocols detailed below
•Evidence level: Anecdotal Reports
•See community reports below
•Stacking patterns detailed below

Clinical vs. Community Protocol Differences

How community-reported protocols differ from clinical research protocols.

Aspect	Clinical Approach	Community Approach	Significance
Availability	CT-388 (RO7795068) is in Phase 2 development at Roche/Genentech (acquired via Carmot Therapeutics). Phase 3 trials planned for 2026.	No community access exists. CT-388's proprietary sequence and early development stage mean no research chemical vendors offer the compound. Community discussion is entirely analytical.	high Unlike some investigational peptides that appear from research chemical vendors, CT-388 remains unavailable due to its proprietary nature and early development stage.
Signal-Biased Mechanism	CT-388 is a signal-biased dual GLP-1/GIP agonist that minimizes beta-arrestin recruitment and receptor internalization, potentially maintaining receptor sensitivity over time.	Community interest focuses on whether signal-biased agonism will translate to better sustained efficacy, fewer side effects, or reduced tolerance compared to conventional agonists like tirzepatide.	moderate The Phase 2 result of 22.5% weight loss at 48 weeks with no plateau observed has generated significant community interest in the signal-biased approach.

Compare these community approaches with published research findings.

Sources

Reddit r/Peptides|CT-388 and next-generation obesity pipeline discussions(accessed 2026-02-16)
Reddit r/Semaglutide|Roche CT-388 Phase 2 results discussion(accessed 2026-02-16)

Community Evidence Overview#

This page presents aggregated community protocols and anecdotal reports for CT-388 (RO7795068). The information below is gathered from Reddit communities and online forums. This is not clinical evidence and should not be used as medical guidance.

CT-388 has no community use data as it remains in early clinical development with a proprietary sequence. All community discussion is analytical, focusing on Phase 2 results and the signal-biased mechanism.

Early Development Stage#

CT-388 is in Phase 2 clinical development by Roche/Genentech, with Phase 3 planned for 2026. The compound's proprietary sequence and early development stage mean no community access exists through any channel.

Community Interest Drivers#

Community discussion about CT-388 focuses on:

22.5% weight loss at 48 weeks: Competitive with tirzepatide results but at an earlier trial stage
No plateau observed: Weight loss curve showed no signs of plateauing, generating excitement about potential for even greater long-term efficacy
Signal-biased mechanism: Theoretical advantage of sustained receptor sensitivity
Roche backing: Major pharmaceutical company involvement suggests robust development pathway

Important Caveats#

CT-388 is in Phase 2 development only
No community access exists; proprietary compound
Phase 2 results require Phase 3 confirmation
No long-term safety or efficacy data available
Community discussion is entirely speculative and anticipatory

Subscribe to see vendor options

Free access to verified vendor scores, pricing, and suppliers.

150+ peptide profiles · 30+ comparisons · 18 research tools

Already subscribed?

Frequently Asked Questions About CT-388

Explore Further

Calculate your dose

Reconstitution volumes, injection doses, and supply planning

⚠️

Medical Disclaimer

This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.

Compare Tools Vendors